Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Oslo, Norway, 25 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 25 April 2024, regarding the final results of the partially guaranteed share offering (the "Offering").

As of this date, the Company has been informed that the following primary insiders and close associates to primary insiders have been allocated new shares in the Offering, as set out below:

Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog, subscribed for 724,448.00 shares in the Offering. Hifo Invest AS was allocated 724,448.00 shares at a price of NOK 5.24 per share.

Saturn Invest AS, a close associate to primary insider, Brynjar Forbergsskog, subscribed for 724,448.00 shares in the Offering. Saturn Invest AS was allocated 724,448.00 shares at a price of NOK 5.24 per share.

Øystein Rekdal, primary insider, subscribed for 9,550.00 shares in the Offering. Øystein Rekdal was allocated 9,550.00 shares at a price of NOK 5.24 per share.

Gjest Andreas Breistein, primary insider, subscribed for 10,000.00 shares in the Offering. Gjest Andreas Breistein was allocated 10,000.00 shares at a price of NOK 5.24 per share.

Baldur Sveinbjørnsson, primary insider, subscribed for 4,000.00 shares in the Offering. Baldur Sveinbjørnsson was allocated 4,000.00 shares at a price of NOK 5.24 per share.

Please see the attached forms for further details about the transactions.

Disclosure regulation:

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix:

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.